antirheumatic agents

Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy—a tertiary centre experience in an Appalachian state
Elise Danielle McVeigh, Amna Batool, Arnold Stromberg, Ahmed Abdel-Latif, Nayef Mohammed Kazzaz

Lupus Science & Medicine May 2021, 8 (1) e000467; DOI: 10.1136/lupus-2020-000467
Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre
Deanna D Hill, Amanda M Eudy, Peter J Egger, Qinggong Fu, Michelle A Petri

Lupus Science & Medicine Apr 2021, 8 (1) e000446; DOI: 10.1136/lupus-2020-000446
Rheumatologists’ perspective on hydroxychloroquine guidelines
James Winebrake, Leila Khalili, Julia Weiner, Yevgeniya Gartshteyn, Lisa Park, Anca D Askanase

Lupus Science & Medicine Nov 2020, 7 (1) e000427; DOI: 10.1136/lupus-2020-000427
Impact of COVID-19 pandemic on SLE: beyond the risk of infection
Alice Horisberger, Laura Moi, Camillo Ribi, Denis Comte

Lupus Science & Medicine May 2020, 7 (1) e000408; DOI: 10.1136/lupus-2020-000408

Main menu